Questions
PT-141 questions, answered plainly
Direct, cited answers to the most common PT-141 (bremelanotide) questions — definitions, mechanism, dosing as labeled, and access.
Can you get PT-141 through telehealth?
PT-141 (bremelanotide) is a prescription drug for its approved use, so access runs through a prescriber. Peer-reviewed work has described how remote evaluation operates in sexual medicine, including the access considerations clinicians weigh [8], and a 2025 study tracked telemedicine growth in sexual medicine during the pandemic [13]. This site explains that literature; it is not a clinic and offers no prescriptions.
What is PT-141?
PT-141 is a synthetic alpha-MSH analogue that acts as an agonist at melanocortin receptors (MC3R and MC4R) found mainly in the central nervous system [1]. It is the same molecule as bremelanotide, FDA-approved in 2019 for low sexual desire with distress in premenopausal women [3][7]. It works in the brain, not on blood vessels [1].
What is PT-141 peptide?
As a peptide, PT-141 is a cyclic heptapeptide — seven amino acids closed into a ring by a lactam bridge — built as an analogue of the natural melanocortin alpha-MSH [1]. The ring makes it more stable than a straight-chain peptide. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, and its nonproprietary name is bremelanotide [3].
What does the PT-141 peptide do?
The PT-141 peptide switches on central melanocortin receptors, mainly MC4R, in hypothalamic circuits tied to sexual desire [1]. In trials it improved sexual desire and reduced desire-related distress in premenopausal women with HSDD [3], and in a brain scan study it raised desire for up to 24 hours and changed central processing of erotic stimuli [5].
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved for one use: acquired, generalized hypoactive sexual desire disorder in premenopausal women [7]. Every other use — in men, in postmenopausal women, for erectile dysfunction, or for performance — is off-label or investigational [1][7][14]. We label non-HSDD uses accordingly throughout this site.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development and research-chemical name; bremelanotide is the international nonproprietary name for the same molecule [3]. The approved injectable medicine and the compound called PT-141 are chemically identical, though the unregulated "research chemical" form is not made or quality-checked like the approved drug [7].
What is bremelanotide?
Bremelanotide is the nonproprietary name for PT-141, a melanocortin receptor agonist approved in 2019 for low sexual desire with distress in premenopausal women [3][7]. It is a synthetic cyclic peptide analogue of alpha-MSH that acts centrally on MC4R rather than on blood vessels [1].
How does PT-141 work?
PT-141 works by activating central melanocortin receptors, chiefly MC4R, in hypothalamic circuits that govern sexual motivation [1]. This engages dopaminergic signalling linked to desire-driven behavior [2]. Unlike erection pills, which act peripherally on blood vessels, PT-141 acts on the brain's desire circuitry [1].
What receptors does PT-141 act on?
PT-141 is an agonist at the melanocortin MC4 receptor (its main target) and the MC3 receptor, both concentrated in the central nervous system [1]. MC4R sits in hypothalamic circuits that govern both sexual desire and appetite, while peripheral MC1R activation explains the hyperpigmentation seen with repeated dosing [7].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on MC4R in the hypothalamus, increasing c-Fos (a marker of neuronal activity) and altering brain processing of sexual stimuli [1][5]. It does not act on vascular smooth muscle the way PDE-5 inhibitors do, which is the core mechanistic difference [1].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that switches on melanocortin receptors — a family of five (MC1R–MC5R) that respond to peptides like alpha-MSH [1]. PT-141 targets the central MC3R and MC4R subtypes [1]. This class is also a target for metabolic disorders such as obesity [11].
Does PT-141 increase testosterone?
No. PT-141 does not act through the hormone (HPG) axis and does not directly raise testosterone [1]. It acts centrally on melanocortin receptors to influence sexual desire, a mechanism separate from testosterone signalling [1]. Claims that it boosts testosterone are not supported by the published mechanism.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on melanocortin MC4R to influence sexual desire [1]. They target different problems through different mechanisms. A 2024 Phase 2 study even began testing the two together for male erectile dysfunction, which is investigational [14].
What is the PT-141 dosage?
The approved label dose of bremelanotide is 1.75 mg injected subcutaneously, as needed, with no more than one dose per 24 hours and no more than eight doses per month [7]. That is documented as the labeled dose, not a recommendation. The terminal half-life is about 2.7 hours [7].
How much PT-141 should I take?
This site recommends no dose to any individual. The published approved-label dose for bremelanotide in HSDD is 1.75 mg subcutaneously as needed within a monthly ceiling [7]. Any personal dosing decision belongs to a qualified prescriber, not to a research digest; we describe what was studied and labeled, nothing more.
How much PT-141 to inject?
We do not give self-injection instructions. For the approved indication, the label specifies 1.75 mg subcutaneously as needed [7]. The unregulated research-chemical form has no oversight of identity, purity, or concentration, so even the contents of such a vial are unverified [7]. This is described as labeled fact, not guidance.
What is the PT-141 dosage for women?
The reviewed dosage for women is the HSDD label dose: bremelanotide 1.75 mg subcutaneously as needed [7]. Pre-approval Phase 2 dose-finding in women tested 0.75, 1.25, and 1.75 mg [7]. In preclinical female-rat work, the compound selectively increased desire-driven sexual behavior without affecting reflexes or movement [2].
How do you reconstitute PT-141?
The approved bremelanotide product is a prefilled pharmaceutical, so reconstitution does not apply to it [7]. "Reconstitution" questions concern the unregulated research-chemical form, which sits outside the approval framework with no quality oversight; this site provides no reconstitution or preparation instructions [7].
How do you take PT-141?
For the approved use, the label route is subcutaneous — under the skin — taken as needed at least 45 minutes before anticipated activity [7]. This site does not provide self-administration instructions; it reports the labeled route as documented. Early research also explored intranasal and intravenous routes [7].
How often can you take PT-141?
The label limits the approved dose to no more than once per 24 hours and no more than eight doses per month [7]. In the 52-week extension, sustained use showed no new safety signals, with nausea (40.4%), flushing (20.6%), and headache (12.0%) as the main drug-related events [4]. These are labeled limits and trial data, not advice.
What is the approved bremelanotide dose?
The approved bremelanotide dose is 1.75 mg subcutaneously as needed, established by the RECONNECT Phase 3 trials (1,267 premenopausal women with HSDD), where it improved sexual desire (FSFI-desire +0.35, P<.001) and reduced distress (FSDS-DAO item 13 −0.33, P<.001) over 24 weeks [3][7].
How long does PT-141 last?
In the blood, PT-141 has a terminal half-life of about 2.7 hours (range 1.9–4.0) after subcutaneous dosing, with peak levels around 0.5–1.0 hours [7]. The desire effect can outlast the drug: a brain-imaging study found increased sexual desire for up to 24 hours after a single dose [5].